Literature DB >> 24246565

Response to "survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach" by Bagust and Beale.

Nicholas R Latimer1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24246565     DOI： 10.1177/0272989X13511302

Source DB:  PubMed          Journal:  Med Decis Making        ISSN： 0272-989X            Impact factor:   2.583


× No keyword cloud information.
  4 in total

1.  After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?

Authors:  Mark Sculpher; Stephen Palmer
Journal:  Pharmacoeconomics       Date:  2020-03       Impact factor: 4.981

Review 2.  Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Sabine E Grimm; Nigel Armstrong; Bram L T Ramaekers; Xavier Pouwels; Shona Lang; Svenja Petersohn; Rob Riemsma; Gillian Worthy; Lisa Stirk; Janine Ross; Jos Kleijnen; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

3.  Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).

Authors:  Lisa Masucci; Jaclyn Beca; Mona Sabharwal; Jeffrey S Hoch
Journal:  Pharmacoecon Open       Date:  2017-12

4.  Dynamic and Flexible Survival Models for Extrapolation of Relative Survival: A Case Study and Simulation Study.

Authors:  Benjamin Kearns; Matt D Stevenson; Kostas Triantafyllopoulos; Andrea Manca
Journal:  Med Decis Making       Date:  2022-06-29       Impact factor: 2.749
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.